Download PDF
Thromb Haemost 1999; 81(02): 301-305
DOI: 10.1055/s-0037-1614461
Review Articles
Schattauer GmbH

Profile of Recombinant Pro-urokinase Given by Intraarterial versus Intravenous Routes of Administration in a Canine Thrombosis Model

Sandra E. Burke
1   From Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois, USA
,
Nathan L. Lubbers
1   From Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois, USA
,
Richard A. Nelson
1   From Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois, USA
,
Craig D. Wegner
1   From Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois, USA
,
Bryan F. Cox
1   From Pharmaceutical Discovery, Abbott Laboratories, Abbott Park, Illinois, USA
› Author Affiliations
Further Information

Publication History

Received17 October 1998

Accepted after resubmission18 September 1998

Publication Date:
08 December 2017 (online)

    Permissions and Reprints

Summary

Catheter-directed thrombolysis has gained increasing acceptance for the treatment of patients who present with vascular occlusion; however, intravenous injection may be preferable in selected patients. Recombinant prourokinase (r-proUK) is a recently-developed fibrin-selective thrombolytic agent with specificity for clot-bound plasminogen. To compare the effects of r-proUK on clot lysis and restoration of blood flow when injected by either intraarterial or intravenous routes of administration, we utilized a dog model of arterial thrombosis in which a radiolabelled clot is formed in the femoral artery. The r-proUK was given by intravenous infusion to one group of 18 animals in doses ranging from 10,000 IU/kg to 100,000 IU/kg; a second group of 27 dogs was treated with r-proUK administered by the intra-arterial route in a dose range from 300 IU to 10,000 IU. Clot lysis was measured by monitoring the loss of counts from the radiolabelled clot over time; blood flow was also monitored throughout the experimental period. Animals which received intravenous treatment showed dose-related clot lysis ranging from 14% to 70% at 2 h, while those which received intra-arterial infusions showed lysis ranging from 22% to 79% over the same period. For similar degrees of clot lysis attained at the highest dose levels of 100,000 IU/kg and 10,000 IU, blood flow was restored to 77% and 35% of control levels in dogs which received intravenous and intraarterial treatment, respectively. The hemostatic protein fibrinogen was not reduced in any of the treatment groups. The results indicate that 100 times more intravenous than intra-arterial r-proUK is required to produce similar clot lysis in this canine model, and that the agent can be administered at this level without induction of a systemic lytic state.

 

  • References

  • 1 Ouriel K, Veith F, Sasahara A. Thrombolysis or peripheral arterial surgery: Phase I results. J Vasc Surg 1996; 23: 64-75.
    CrossrefPubMedGoogle Scholar
  • 2 Shortell CK, Ouriel K. Thrombolysis in acute peripheral arterial occlusion: predictors of immediate success. Ann Vasc Surg 1994; 8: 59-65.
    CrossrefPubMedGoogle Scholar
  • 3 McNamara T. Role of thrombolysis in peripheral arterial occlusion. Am J Med 1987; 83 suppl 2A 6-10.
    PubMedGoogle Scholar
  • 4 Cragg AH, Smith TP, Corson JD, Nakagawa N, Castaneda F, Kresowik TF, Sharp WJ, Shamma A, Berbaum KS. Two urokinase dose regimens in native arterial and graft occlusions: initial results of a prospective, randomized clinical trial. Radiology 1991; 178: 681-6.
    CrossrefPubMedGoogle Scholar
  • 5 Kandarpa K, Chopra PS, Aruny JE, Polak JF, Donaldson MC, Whittemore AD, Mannick JA, Goldhaber SZ, Meyerovitz MF. Intraarterial thromboly-sis of lower extremity occlusions: prospective, randomized comparisons of forced periodic infusion and conventional slow continuous infusion. Radiology 1993; 188: 861-7.
    CrossrefPubMedGoogle Scholar
  • 6 Earnshaw J, Westby J, Gregson R, Makin G, Hopkinson B. Local thrombolytic therapy of acute peripheral arterial ischaemia with tissue plasminogen activator: a dose-ranging study. Br J Surg 1988; 75: 1196-200.
    CrossrefPubMedGoogle Scholar
  • 7 Graor R, Olin J, Bacharach M. Comparison of tPA and urokinase for peripheral arterial thrombolysis. J Vasc Med Biol 1993; 4/5: 311-4.
    PubMedGoogle Scholar
  • 8 Meyerovitz M, Goldhaber S, Reagan K, Polak J, Kandarpa K, Grassi C, Donovan B, Bettmann M, Harrington D. Recombinant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial. Radiology 1990; 175: 75-8.
    CrossrefPubMedGoogle Scholar
  • 9 Ward A, Andaz S, Bygrave S. Peripheral thrombolysis with tissue plasminogen activator. Arch Surg 1994; 129: 861-5.
    CrossrefPubMedGoogle Scholar
  • 10 Badylak SF, Voytik S, Henkin J, Burke SE. The protective effect of lyS-plasminogen against thrombosis in a dog model of arterial thrombosis. Fibrinolysis 1990; 4 (Suppl. 03) Suppl A131.
    PubMedGoogle Scholar
  • 11 Pannell R, Gurewich V. Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 1986; 67: 1215-23.
    PubMedGoogle Scholar
  • 12 Badylak SF, Poehlman E, Williams C, Klabunde RE, Henkin J. Simple canine model of arterial thrombosis with endothelial injury suitable for investigation of thrombolytic agents. J Pharmacol Methods 1988; 19: 293-304.
    CrossrefPubMedGoogle Scholar
  • 13 Burke SE, Lubbers NL, Nelson RA, Henkin J. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model. Thromb Haemost 1993; 4: 375-80.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Lo K-M, Gillies SD. High level expression of human proteins in murine hybridoma cells: induction by methotrexate in the absence of gene amplification. Biochimica et Biophysica Acta 1991; 1088: 217-24.
    CrossrefPubMedGoogle Scholar
  • 15 Vermylen C, De Vreker RA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chemica Acta 1963; 8: 418-24.
    PubMedGoogle Scholar
  • 16 Janosik J, Bettmann M, Kaul A, Souney P. Therapeutic alternatives for subacute peripheral arterial occlusion: comparison by outcome, length of stay, and hospital charges. Invest Radiol 1991; 26: 921-5.
    CrossrefPubMedGoogle Scholar
  • 17 The STILE Investigators (Appendix A). Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. Annals of Surgery 1994; 220-3 251-68.
    PubMedGoogle Scholar
  • 18 McNamara TO, Fischer JR. Thrombolysis of peripheral arterial and graft occlusions: Improved results using high-dose urokinase. Am J Roent 1985; 144: 769-75.
    CrossrefPubMedGoogle Scholar
  • 19 Lonsdale RJ, Berridge DC, Earnshaw JJ, Harrison JD, Gregson RHS, Wenham PW, Hopkinson BR, Makin GS. Recombinant tissue-type plasminogen activator is superior to streptokinase for local intra-arterial thrombolysis. Br J Surg 1992; 79: 272-5.
    CrossrefPubMedGoogle Scholar
  • 20 Russell D, Madden KP, Clark WM, Justin JA. Tissue plasminogen activator cerebrovascular thrombolysis in rabbits is dependent on the rate and route of administration. Stroke 1992; 23: 388-93.
    CrossrefPubMedGoogle Scholar
  • 21 Gu S, Ducas J, Wolfe K, Patton JN, Prewitt RM. Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs. intravenous administration. Chest 1991; 100: 201-6.
    CrossrefPubMedGoogle Scholar
  • 22 Berridge DC, Gregson RHS, Hopkinson BR, Makin GS. Randomized trial of intra-arterial recombinant tissue plasminogen activator, intravenous recombinant tissue plasminogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis. Br J Surg 1991; 78: 988-95.
    CrossrefPubMedGoogle Scholar
  • 23 Tomada H. Experimental study on the comparative thrombolytic effects of intracoronary and intravenous administration of urokinase. Japan Heart J 1986; 27: 259-65.
    CrossrefPubMedGoogle Scholar
  • 24 Ostermann H, Schmitz-Huebner U, Windeler J, Bär F, Meyers J. van de Loo for the PRIMI Trial Study Group. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction – Results from the PRIMI Trial. Europ Hear J 1992; 13: 1225-32.
    PubMedGoogle Scholar
  • 25 Bovill EG, Tracy RB, Knatterud GL, Stone PG, Nasmith J, Gore JM, Thompson BW, Tofler GH, Kleiman NS, Cannon C, Braunwald E. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, Phase IIIB Trial). Am J Cardiol 1997; 79: 391-6.
    CrossrefPubMedGoogle Scholar
  • 26 Tracy RP, Kleiman NS, Thompson B, Cannon CP, Bovill EG, Brown RG, Collen D, Mahan E, Mann KG, Rogers WJ, Sopko G, Stump DC, Williams DO. Zaret BL for the TIMI II investigators. Relation of coagulation parameters to patency and recurrent ischemia in the Thrombolysis in Myocardial Infarction (TIMI) Phase II Trial. Am Heart J 1998; 135: 29-37.
    CrossrefPubMedGoogle Scholar
  • 27 Benedict CR, Refino CJ, Keyt BA, Pakala R, Paoni NF, Thomas GR, Bennett WF. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92: 3032-40.
    CrossrefPubMedGoogle Scholar
  • 28 Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D. the TAMI Study Group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 1222-30.
    CrossrefPubMedGoogle Scholar
  • 29 Stump DC, Lijnen HR, Collen D. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120-6.
    PubMedGoogle Scholar
  • 30 Gurewich V. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. JACC 1987; 10: 16B-21B.
    CrossrefPubMedGoogle Scholar